Fujita F, Fujita M, Nakano Y, Hayata S, Taguchi T
Gan To Kagaku Ryoho. 1984 Oct;11(10):2212-20.
Human lactate dehydrogenase (LDH) was universally detected and quantified from sera of nude mice bearing human tumors. The patterns of LDH isozyme in sera reflected exactly those in each tumor extract, and remained unchanged over several generations. In 16 human cancers (7 gastric, 4 colorectal, 2 pancreatic and 3 breast) examined, human LDH levels in serum showed proportional increase as the transplanted tumors grew. Assessment of experimental chemotherapy by measuring the LDH levels of a treated group versus a control group was compared with that obtained by calculating the tumor weight during (14 tests) or after (61 tests) treatments. The percentage inhibition assessed by LDH level was strongly correlated to inhibition rate assessed by tumor weight. Moreover, LDH expressed more rapidly the inhibitory effect of an administered agent than tumor weight. If the drug was effective, serum LDH level in the treated group exhibited a temporary sharp rise within 2 days, thereafter decreasing to a lower level than that of the control. These results imply usefulness in further clinical application.
在携带人类肿瘤的裸鼠血清中普遍检测并定量了人类乳酸脱氢酶（LDH）。血清中LDH同工酶的模式与每个肿瘤提取物中的模式完全一致，并且在几代中保持不变。在检测的16种人类癌症（7例胃癌、4例结直肠癌、2例胰腺癌和3例乳腺癌）中，随着移植肿瘤的生长，血清中的人类LDH水平呈比例增加。通过测量治疗组与对照组的LDH水平来评估实验性化疗，并与治疗期间（14次试验）或治疗后（61次试验）通过计算肿瘤重量获得的评估结果进行比较。通过LDH水平评估的抑制百分比与通过肿瘤重量评估的抑制率密切相关。此外，LDH比肿瘤重量更快地表达给药药物的抑制作用。如果药物有效，治疗组的血清LDH水平在2天内会出现暂时的急剧上升，此后降至低于对照组的水平。这些结果表明其在进一步临床应用中的有用性。
